CRISPR Therapies Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, and Treatment Outlook | eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego, Inari, Ligandal, CRISPR Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"CRISPR Therapies Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the CRISPR Therapies Pipeline Report: https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years.
• CRISPR Therapies companies working in the treatment market are Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others, are developing therapies for the CRISPR Therapies treatment
• Emerging CRISPR Therapies therapies in the different phases of clinical trials are- BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.
• In December 2023, a significant breakthrough occurred in the realm of CRISPR therapies as Vertex Pharmaceuticals and CRISPR Therapeutics achieved approval from the US Food and Drug Administration (FDA) for exagamglogene autotemcel, following earlier approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Positioned as the inaugural CRISPR therapy to enter the market, exagamglogene autotemcel, marketed as Casgevy, offers a promising one-time treatment option for individuals with sickle cell disease. This therapy involves genetically modified autologous CD34+ cells enriched with human hematopoietic stem and progenitor cells, which undergo ex vivo editing using CRISPR-Cas9 technology.
• In September 2023, Vertex Pharmaceuticals and CRISPR Therapeutics jointly announced the completion of discussions with the US Food and Drug Administration (FDA) regarding exagamglogene autotemcel (exa-cel). Following these discussions, the FDA granted a rolling review for exa-cel as a potential treatment for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
• In August 2023, CRISPR Therapeutics has commenced a single-dose, open-label research endeavor focusing on participants diagnosed with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). This study aims to assess the safety and effectiveness of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

CRISPR Therapies Overview


Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:
• BEAM-301: Beam Therapeutics
• TNG260: Tango Therapeutics
• CTX 130: CRISPR therapeutics
• CB-010: Caribou Biosciences, Inc.
• KSQ-4279: KSQ Therapeutics
• NTLA-2002: Intellia Therapeutics, Inc.
• LBP-EC01: Locus Biosciences
• CTX001: CRISPR Therapeutic

CRISPR Therapies Route of Administration
CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

CRISPR Therapies Molecule Type
CRISPR Therapies Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

CRISPR Therapies Pipeline Therapeutics Assessment
• CRISPR Therapies Assessment by Product Type
• CRISPR Therapies By Stage and Product Type
• CRISPR Therapies Assessment by Route of Administration
• CRISPR Therapies By Stage and Route of Administration
• CRISPR Therapies Assessment by Molecule Type
• CRISPR Therapies by Stage and Molecule Type

DelveInsight's CRISPR Therapies Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the CRISPR Therapies Therapeutics Market include:
Key companies developing therapies for CRISPR Therapies are - eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego, Inari, Ligandal, CRISPR Therapeutics, Mammoth Biosciences, Poseida Therapeutics, Beam Therapeutics, Pairwise, Sherlock Biosciences, and others

CRISPR Therapies Pipeline Analysis:
The CRISPR Therapies pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.
• CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

CRISPR Therapies Pipeline Market Drivers
• New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing are some of the important factors that are fueling the CRISPR Therapies Market.

CRISPR Therapies Pipeline Market Barriers
• However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth.

Scope of CRISPR Therapies Pipeline Drug Insight
• Coverage: Global
• Key CRISPR Therapies Companies: Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others
• Key CRISPR Therapies Therapies: BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others
• CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies
• CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers

Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. CRISPR Therapies Report Introduction
2. CRISPR Therapies Executive Summary
3. CRISPR Therapies Overview
4. CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment
5. CRISPR Therapies Pipeline Therapeutics
6. CRISPR Therapies Late Stage Products (Phase II/III)
7. CRISPR Therapies Mid Stage Products (Phase II)
8. CRISPR Therapies Early Stage Products (Phase I)
9. CRISPR Therapies Preclinical Stage Products
10. CRISPR Therapies Therapeutics Assessment
11. CRISPR Therapies Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. CRISPR Therapies Key Companies
14. CRISPR Therapies Key Products
15. CRISPR Therapies Unmet Needs
16 . CRISPR Therapies Market Drivers and Barriers
17. CRISPR Therapies Future Perspectives and Conclusion
18. CRISPR Therapies Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

CRISPR Therapies Epidemiology https://www.delveinsight.com/report-store/crispr-therapies-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'CRISPR Therapies Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.